Zai Lab Limited - ADR earnings per share and revenue
On 06 de nov. de 2025, ZLAB reported earnings of -0.03 USD per share (EPS) for Q3 25, beating the estimate of -0.04 USD, resulting in a 32.43% surprise. Revenue reached 115.36 milhão, compared to an expected 139.44 milhão, with a -17.27% difference. The market reacted with a -5.40% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analistas forecast an EPS of -0.06 USD, with revenue projected to reach 127.63 milhão USD, implying an aumentar of 100.00% EPS, and aumentar of 10.64% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
22 de dez. de 2025 Para Q4 25
Estimativa
-$0.57
Real
-$0.73
Surpresa
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
19 de dez. de 2025 Para Q4 25
Estimativa
-$0.25
Real
-$0.19
Surpresa
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were Zai Lab Limited - ADR's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Zai Lab Limited - ADR reported EPS of -$0.03, beating estimates by 32.43%, and revenue of $115.36M, -17.27% below expectations.
How did the market react to Zai Lab Limited - ADR's Q3 2025 earnings?
The stock price moved down -5.4%, changed from $23.15 before the earnings release to $21.90 the day after.
When is Zai Lab Limited - ADR expected to report next?
The next earning report is scheduled for 25 de fev. de 2026.
What are the forecasts for Zai Lab Limited - ADR's next earnings report?
Based on 4
analistas, Zai Lab Limited - ADR is expected to report EPS of -$0.06 and revenue of $127.63M for Q4 2025.